Shanghai Bio-heart Unit Marks First Commercial Use of Iberis RDN System in Switzerland; Shares Up 5%
MT Newswires Live
Oct 24
Shanghai Bio-heart Biological Technology (HKG:2185) said its subsidiary, Shanghai AngioCare Medical Technology, has completed the first commercial procedure of its Iberis multi-electrode renal artery radiofrequency ablation catheter system in Switzerland, according to a Thursday Hong Kong bourse filing.
Shares of the medical device company gained nearly 5% in Friday morning trade.
The procedure, conducted at University Hospital Basel, was completed without complications or adverse events, the company said.
The project was supported jointly by Biosensors International Group, a subsidiary of Blue Sail Medical (SHE:002382), under an existing partnership covering the EU, Asia-Pacific, and Latin America markets.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.